In vivo behaviour of antibody-drug conjugates for the targeted treatment of cancer

Expert Opinion on Biological Therapy
Hongsheng Xie, Walter A Blättler

Abstract

It is a commonly held belief that most treatments for disseminated cancers are only moderately effective because the agents lack cell-killing mechanisms that act specifically on cancer cells. In antibody-drug conjugates, such nonspecific cytotoxic agents are combined with exquisitely specific monoclonal antibodies that bind to tumour-associated antigens and, thus, get endowed with new pharmacological characteristics. Not only is their activity newly targeted towards tumours and tumour cells, which hopefully renders them more tumour-specific, but they also acquire much of the pharmacokinetic behaviour of the monoclonal antibody component. With the structural composition of a macromolecular protein (the antibody), a small chemical cytotoxic agent and a linker to chemically connect these two molecules, antibody-drug conjugates are some of the most complex pharmacological agents ever developed. Their development over the last 20 years or so owes much to sophisticated in vitro and in vivo preclinical testing. This review attempts to summarise and exemplify many of the factors that had to be considered during the development, with special emphasis on the in vivo pharmacology of these agents.

References

Dec 1, 1992·Current Opinion in Oncology·G Rowlinson-Busza, A A Epenetos
Oct 4, 1989·Journal of the National Cancer Institute·D FitzGerald, I Pastan
Mar 24, 1988·Nature·L RiechmannG Winter
Jan 1, 1994·Journal of Drug Targeting·G A Pietersz, K Krauer
Feb 1, 1994·Proceedings of the National Academy of Sciences of the United States of America·M A RoguskaB C Guild
Mar 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J BaselgaL Norton
Aug 6, 1996·Proceedings of the National Academy of Sciences of the United States of America·C LiuR V Chari
Mar 21, 1998·Proceedings of the National Academy of Sciences of the United States of America·R P JunghansT A Waldmann
Jun 6, 2000·Advanced Drug Delivery Reviews·R V Chari
Sep 23, 2000·Nature·P Carmeliet, R K Jain
Nov 6, 2001·Oncology·B Leyland-Jones
May 29, 2002·Proceedings of the National Academy of Sciences of the United States of America·Tore SeternesBård Smedsrød
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony W TolcherEric K Rowinsky
Apr 5, 2003·Cancer Cell·Gillian Payne
Jun 5, 2003·Nature Biotechnology·Svetlana O DoroninaPeter D Senter
Nov 25, 2003·The Journal of Pharmacology and Experimental Therapeutics·Hongsheng XieWalter A Blättler
Mar 20, 2004·Science·Theresa M Allen, Pieter R Cullis
Jul 9, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paul R HelftMark J Ratain
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Oct 27, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin J HamblettJoseph A Francisco
Apr 26, 2005·Methods : a Companion to Methods in Enzymology·William Ying Khee Hwang, Jefferson Foote
Apr 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Otto Zach, Dieter Lutz

❮ Previous
Next ❯

Citations

Aug 10, 2012·The AAPS Journal·Hans K Erickson, John M Lambert
Mar 1, 2011·Therapeutic Delivery·Victor S Goldmacher, Yelena V Kovtun
Jul 7, 2011·Clinical Breast Cancer·Howard A BurrisGail D Lewis Phillips
Jun 8, 2007·Cancer Letters·Yelena V Kovtun, Victor S Goldmacher
Apr 29, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Markus WallesSanela Bilic
Nov 22, 2008·Trends in Biotechnology·Philip G Williams
Jan 11, 2018·Journal of Cellular Physiology·Hadi NasiriJafar Majidi
Feb 2, 2018·Journal of Applied Toxicology : JAT·Sarah TaplinRobert Johnson
Dec 13, 2006·ChemMedChem·Jascha-N RybakDario Neri
Jun 10, 2008·The Cancer Journal·Paul J Carter, Peter D Senter
May 21, 2016·Nursing Philosophy : an International Journal for Healthcare Professionals·Bernard M Garrett
Apr 30, 2017·Chemical Science·Thomas H PillowJohn A Flygare
Jul 17, 2015·Bioscience Reports·Christina Peters, Stuart Brown
Mar 5, 2008·Bioconjugate Chemistry·Stephen C AlleyPeter D Senter

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.